Ads
related to: medications used for ischemic stroke treatment the brain can result in paindiscoverpanel.com has been visited by 10K+ users in the past month
assistantmagic.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
[citation needed] Central post-stroke pain (CPSP) is neuropathic pain which is caused by damage to the neurons in the brain (central nervous system), as the result of a vascular injury. One study found that up to 8% of people who have had a stroke will develop central post-stroke pain, and that the pain will be moderate to severe in 5% of those ...
Cerebral infarction, also known as an ischemic stroke, is the pathologic process that results in an area of necrotic tissue in the brain (cerebral infarct). [1] In mid to high income countries, a stroke is the main reason for disability among people and the 2nd cause of death. [2]
A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. [1] As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs have been tested in clinical trials to provide cerebroprotection.
When applied to protecting the brain from the effects of acute ischemic stroke, neuroprotectants are often called cerebroprotectants. Over 150 drugs have been tested in clinical trials, leading to the regulatory approval of tissue plasminogen activator in several countries, and the approval of edaravone in Japan.
Alteplase (t-PA) is an effective medication for acute ischemic stroke. When given within 3 hours, treatment with tpa significantly improves the probability of a favourable outcome versus treatment with placebo. [citation needed] The outcome of brain ischemia is influenced by the quality of subsequent supportive care.
The structure of desmoteplase is similar to rt-PA (), but it does not contain the plasmin-sensitive cleavage site and the lysine-binding Kringle 2 domain.As a result, desmoteplase, in comparison to rt-PA, has high fibrin selectivity (100,000- v. 550-fold increase in catalytic activity), an absence of neurotoxicity, and no apparent negative effect on the blood–brain barrier.
Many risk factors can lead to a stroke, but the magnitude of risk from some of these conditions or behaviors may have a stronger association with severe stroke compared with mild stroke, according ...
Ischemic stroke is caused by interruption of the blood supply to the brain, while hemorrhagic stroke results from the rupture of a blood vessel or an abnormal vascular structure. About 87% of stroke is ischemic, with the rest being hemorrhagic. Bleeding can develop inside areas of ischemia, a condition known as "hemorrhagic transformation." It ...
Ads
related to: medications used for ischemic stroke treatment the brain can result in paindiscoverpanel.com has been visited by 10K+ users in the past month
assistantmagic.com has been visited by 10K+ users in the past month